Capsule size is determined by more than the target dose. Blend density, particle characteristics, flowability, ingredient count, and required fill weight all affect whether a formula can be filled consistently.

The ranges below are preliminary planning references only. Final capsule size and fill weight should be confirmed after evaluating the actual blend density and completing a filling trial.

*Actual fill weight depends on formulation density, powder characteristics, equipment, and target fill-weight tolerance.

What Determines the Actual Fill Weight?

Sulforaphane powders and broccoli sprout extracts can vary significantly in bulk density and flow characteristics depending on raw material grade, particle size, carrier system, and processing history.

During formulation development, bulk and tapped density can be evaluated together with powder flow and particle characteristics. These data help determine the practical fill volume and support the selection of capsule size and filling parameters.

A Practical Feasibility Rule

If the target active dose already occupies most of the available capsule volume, adding vitamins, minerals, or botanical extracts may push the formula beyond the practical fill capacity of a single capsule.

Depending on the actual blend, possible solutions include:

• Selecting a larger capsule size
• Using multiple capsules per serving
• Using a more concentrated raw material
• Adjusting the formula composition
• Selecting a different delivery system
• Physically separating incompatible or high-volume components

The correct solution should be determined from the actual formula and raw material properties, rather than from a generic capsule-size chart alone.

What We Confirm Before Production

Before finalizing the capsule specification, the formulation is reviewed for:

Target active dose → Blend density → Fill volume → Capsule size → Filling performance → Weight consistency

This feasibility check helps identify capacity or filling issues before the formula moves into commercial production.

Quality control starts before production. Raw-material identity, active content, myrosinase activity where applicable, in-process controls, finished-product testing, batch release, and change control are defined against the approved product specification.

Raw Material QC

Raw-material control is the first step in batch consistency. Depending on the material and specification, incoming materials may be evaluated for:

• Identity: IR, HPLC retention time, TLC, or another appropriate identification method against the approved reference or specification
• Active content: HPLC assay for sulforaphane, glucoraphanin, or other specified actives
• Heavy metals: Lead, cadmium, mercury, and arsenic according to the applicable specification
• Microbiology: Total aerobic count, yeast and mold, Enterobacteriaceae, and other required parameters
• Contaminants: Pesticide multi-residue and residual-solvent testing where applicable to botanical extracts

The purpose is not simply to confirm that a raw material “passes testing,” but to verify that it matches the material specification approved for the project.

Finished Product QC

Finished-product testing is performed against the approved specification and label-claim target. Depending on the formula, this may include:

• Active assay: HPLC quantification of the specified active
• Myrosinase activity: Activity testing for GR + myrosinase formulas when enzyme activity is a defined product specification
• Content uniformity: USP <905> or an equivalent applicable method
• Physical testing: Weight variation, disintegration, and dissolution where applicable to the dosage form and specification
• Microbiology: Testing against the approved finished-product microbiological limits

For GR + myrosinase products, enzyme activity can be treated as a distinct quality attribute rather than assuming that the presence of myrosinase automatically indicates adequate activity.

Batch-to-Batch Control

For B2B brands, consistency between production batches is often more important than a single passing test result.

Each batch is released against approved raw-material, in-process, and finished-product specifications. The applicable release documentation can include the Certificate of Analysis and completed batch production records.

Where defined by the quality system, retain samples are maintained under controlled conditions for the required retention period to support future investigation, stability review, or batch-traceability needs.

Raw Material Change Control

Raw-material consistency also depends on controlling supplier and specification changes.

A supplier substitution, material-grade change, or other significant raw-material change should not be treated as an automatic one-to-one replacement. Where applicable, the change is reviewed against the approved specification and may require customer approval, documentation review, and equivalency assessment before use.

This matters because a finished-product assay alone cannot fully demonstrate batch consistency if the incoming raw material has changed in identity, potency, carrier system, or other critical characteristics.

What This Means for Buyers

Before production, the key quality parameters are defined rather than left to a generic “standard QC” package.

Approved raw material → Incoming QC → In-process controls → Finished-product assay → Batch release → Retained samples & traceability

For formulas containing sulforaphane, glucoraphanin, or myrosinase, the applicable active and activity specifications can be reviewed with the buyer before the commercial batch is produced.

Packaging should be considered as part of stability planning, not selected only as a branding or presentation decision after the formula has been finalized.

For sulforaphane capsule products, the appropriate packaging configuration depends on the active system, moisture and light sensitivity, target shelf life, distribution conditions, and commercial format. A higher-barrier package is not automatically a better choice; the objective is to provide appropriate protection without adding unnecessary cost or complexity.

Packaging Options

Final packaging selection should be based on the actual formulation and stability requirements rather than applying one standard package to every sulforaphane product.

Stability Testing

Stability protocols are established according to the commercial formulation, packaging configuration, intended shelf life, storage conditions, and applicable market requirements.

Depending on the product, the stability program may evaluate:

• Active assay: Retention of the specified sulforaphane or glucoraphanin content over the proposed shelf life
• Myrosinase activity: Activity retention for GR + myrosinase formulas where enzyme activity is a defined product specification
• Moisture: Moisture content and, where appropriate, Karl Fischer analysis for powder materials
• Physical condition: Capsule integrity, appearance, disintegration, or other relevant physical attributes
• Microbiological stability: Applicable microbiological parameters during storage

Accelerated conditions such as 40°C / 75% RH may be incorporated into the stability program where appropriate, together with real-time monitoring under the proposed storage conditions.

Stability Is Specific to the Formula and Package

A stability result from one sulforaphane formula should not automatically be applied to another formula.

Changes in active form, extract specification, excipient system, moisture sensitivity, capsule configuration, or packaging can affect stability performance. The same active ingredient may therefore require a different stability approach when the formulation or packaging configuration changes.

For this reason, final shelf-life claims should be based on stability data generated or justified for the specific commercial formulation and packaging combination, rather than on a generic ingredient-level shelf-life assumption.

What to Confirm Before Production

Before finalizing the packaging and shelf-life target, the following should be aligned:

Formula → Active specification → Packaging → Storage conditions → Stability protocol → Shelf-life target

For qualified projects, applicable stability information and supporting documentation can be reviewed under NDA where appropriate.

If you already have a target shelf life, packaging format, or destination-market requirement, these parameters can be reviewed during formulation development before the commercial package is finalized.

Commercial production should not be the first time a formulation is tested under manufacturing conditions. Our workflow is structured to identify technical, material, process, and release risks before the project reaches full-scale production.

1. Formula & Feasibility Review

We first review the active system, target dosage, capsule size, delivery technology, ingredient combination, and destination-market requirements.

This stage is used to identify potential issues such as capsule capacity, powder characteristics, ingredient compatibility, active stability, or packaging requirements before the formula is locked.

Risk addressed: Formula feasibility · Capsule capacity · Compatibility · Regulatory requirements

2. Raw Material Qualification

Raw materials are reviewed against the approved specification before use. Depending on the material, this may include supplier documentation, identity verification, active-content testing, contaminant screening, and other applicable incoming QC requirements.

Raw materials are released for production only after the applicable acceptance criteria have been met.

Risk addressed: Raw-material identity · Potency variation · Supplier/specification changes · Contaminant risk

3. Sample Development

Laboratory or development-scale samples are prepared to evaluate the proposed formula under practical processing conditions.

Depending on the project, the review may include capsule appearance, fill weight, powder flow, blend uniformity, active assay, and basic physical characteristics.

This stage gives the buyer an opportunity to adjust the formula before committing to a larger production batch.

Risk addressed: Fill-weight problems · Flowability · Formula adjustment · Initial product performance

4. Pilot / Process Validation

Where required by the project, a pilot or process-validation run is used to confirm that the formulation can move from development scale toward commercial manufacturing.

Process parameters, filling performance, blend behavior, active assay, and other critical characteristics can be reviewed before full-scale production.

The objective is to identify scale-up issues while they are still manageable rather than after the commercial batch has been produced.

Risk addressed: Scale-up · Process consistency · Filling performance · Batch reproducibility

5. Commercial Production & QC Release

Once the formula and process have been approved, commercial production is performed under the applicable GMP controls and approved manufacturing specifications.

In-process controls and finished-product testing are applied according to the project specification. The batch is released only after the applicable quality and documentation requirements have been completed.

Risk addressed: Batch consistency · Finished-product quality · Release compliance · Documentation

6. Packaging, Final Release & Shipment

The finished product is packaged according to the approved packaging specification, labeling requirements, and shipping configuration.

Final QA review and applicable release documentation are completed before shipment, including the Certificate of Analysis and other required export or project documents.

Risk addressed: Packaging compliance · Labeling errors · Release documentation · Shipment readiness

Why This Workflow Matters to Buyers

The purpose of the workflow is not to add unnecessary development steps. It is to move potential problems to the earliest practical stage, when they are easier and less costly to correct.

A typical project therefore moves through:

Formula feasibility → Raw-material qualification → Sample → Pilot / validation → Commercial production → QC release → Shipment

For a sulforaphane project, this staged approach can help identify issues such as capsule capacity, powder flow, active assay, ingredient compatibility, myrosinase activity, or packaging requirements before the larger production commitment is made.

For a manufacturing project, facility claims are more useful when they can be supported by documentation, an audit, or other appropriate verification. Qualified buyers can review applicable manufacturing, quality, and project documentation during the supplier evaluation process.

Supporting documentation can be provided to qualified buyers under NDA where appropriate. Facility audits, third-party inspections, and applicable regulatory inspections can be supported as required by the project.

The purpose of this information is not simply to demonstrate facility size, but to give buyers practical points they can use when evaluating manufacturing capability and project readiness.

A formulation that looks workable on paper may still require adjustment before commercial production. The following are common decision points in sulforaphane projects and the factors that may be reviewed before the formula is finalized.

These are development considerations rather than predetermined outcomes. The appropriate response depends on the actual raw-material specification, blend composition, assay results, physical properties, stability requirements, and target product specifications.

The objective is to identify these issues before commercial production, when formulation changes are easier to make and less disruptive to the project.